Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VERTIS CV
2013-002518-11Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Oct 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing ertugliflozin with placebo (2 arms). Primary endpoint: Major adverse cardiovascular events. Started Oct 2013; status: completed.
02
Drugs
ertugliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2013-002518-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-002518-11.